CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California. A live audio webcast of the presentation wil ...

Applied Digital ( APLD ) stock has seen quite the upward trend in recent times. Towards the latter half of 2025, around mid-October, shares reached the $37 mark. Now, shares have come down quite a bit and can be picked up in the $30 range after theI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific founda ...

Group 1 - Redwire Corporation (RDW) and other small-cap space/defense companies have experienced a bullish run-up over the past month, indicating a need for significant momentum in the sector [1] - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] - The focus is on identifying promising biotechnology companies that are innovating through novel mechanisms of action, first-in-class therapies, or platform technologies [1] Group 2 - The author aims to deliver research that is both technically sound and investment-driven, combining scientific expertise with financial and market analysis [1] - The article highlights the dynamic and rapidly evolving nature of the biotech sector, where breakthrough science can lead to outsized returns [1]

Group 1 - Redwire Corporation (RDW) and other small-cap space/defense companies have experienced a bullish run-up over the past month, indicating a need for significant momentum in the sector [1] - The article emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities in the biotech sector [1] Group 2 - The focus is on identifying promising biotechnology companies that are innovating through novel mechanisms of action, first-in-class therapies, or platform technologies [1] - The analysis aims to deliver research that is both technically sound and investment-driven, combining scientific expertise with financial and market analysis [1]

As I was wading through the waters of all our predictions, readers painted a picture of possibilities and pressure in the private markets.AI, on one hand, is a force multiplier—on the other, it will be unevenly impactful and the losses as the industry consolidates will be staggering. Liquidity, meanwhile, is making a comeback, albeit with a new normal. Velocity is increasing, but so is fragility. There was also an echo of “bigger, fewer, and with more power,” that the wave of capital concentrating at the la ...

Core Viewpoint - Vera Therapeutics announced that the Biologics License Application (BLA) for atacicept, aimed at treating adults with immunoglobulin A nephropathy (IgAN), has been accepted for Priority Review by the FDA, with a target action date of July 7, 2026. If approved, atacicept will provide a self-administered, once-weekly subcutaneous injection for patients [1][7]. Company Overview - Vera Therapeutics is a late clinical-stage biotechnology company focused on developing transformative treatments for serious immunological diseases, with atacicept as its lead product candidate [11]. Product Details - Atacicept is an investigational recombinant fusion protein that targets B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which are cytokines involved in the production of autoantibodies associated with IgAN and other autoimmune kidney diseases [4][11]. - The drug is designed for at-home self-administration, allowing patients to receive treatment conveniently [1][11]. Clinical Trial Results - The BLA submission for atacicept is supported by data from the ORIGIN 3 trial, which demonstrated a 46% reduction in proteinuria from baseline and a statistically significant 42% reduction compared to placebo at week 36 [2][5]. - The ORIGIN Phase 2b clinical trial met its primary and key secondary endpoints, showing significant proteinuria reductions and stabilization of estimated glomerular filtration rate (eGFR) compared to placebo [5][6]. Regulatory Status - Atacicept has received FDA Breakthrough Therapy Designation for IgAN, indicating its potential to provide substantial improvement over existing therapies [9][7]. - The FDA's Priority Review designation highlights the urgent need for new therapies in the IgAN treatment landscape [2][7]. Future Prospects - The ongoing ORIGIN 3 trial involves 431 adults with IgAN and aims to evaluate the long-term effects of atacicept on kidney function, with results expected in 2027 [6][8]. - Vera Therapeutics is also exploring atacicept's efficacy in other autoimmune diseases, expanding its potential market [10][11].

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) ...

BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corpor ...

Core Insights - Monte Rosa Therapeutics announced positive interim data from the Phase 1 clinical study of MRT-8102, a NEK7-directed molecular glue degrader aimed at treating inflammatory conditions linked to the NLRP3 inflammasome, IL-1, and IL-6 [2][3] Study Results - MRT-8102 demonstrated an 85% reduction in C-reactive protein (CRP) levels after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L, indicating a lower cardiovascular disease (CVD) risk [1][3][8] - The study included single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, showing deep and sustained NEK7 degradation across doses from 5 mg to 400 mg [1][3] - A favorable safety profile was observed, with mild to moderate adverse events and no increased infection risk reported [1][7] Future Development Plans - The ongoing GFORCE-1 study of MRT-8102 in subjects with elevated CVD risk is being expanded to include multiple dose levels, with results anticipated in the second half of 2026 [1][5] - A Phase 2 study (GFORCE-2) for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) is planned to be initiated in 2026 [1][5] - Additional indications for MRT-8102 are being evaluated, including metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis [3][5] Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, leveraging its QuEEN™ discovery engine [9]

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calcium Reduced 24-Week Confirmed Disability Worsening and Increased 24-Week Confirmed Disability Improvement Across Progressive Multiple Sclerosis and Its Subtypes, Reinforcing the Drug's Direct Neuroprotective Mechanism of Action – – Long-Term Open-Label Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in ...